Production (Stage)
Allogene Therapeutics, Inc.
ALLO
$1.06
-$0.03-2.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 11.63% | 0.58% | |||
| Gross Profit | -11.63% | -0.58% | |||
| SG&A Expenses | -3.40% | -4.99% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.77% | -0.91% | |||
| Operating Income | -7.77% | 0.91% | |||
| Income Before Tax | -0.40% | 10.25% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.34% | 9.58% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.34% | 9.58% | |||
| EBIT | -7.77% | 0.91% | |||
| EBITDA | -8.44% | 1.01% | |||
| EPS Basic | 2.53% | 10.19% | |||
| Normalized Basic EPS | -1.52% | -2.89% | |||
| EPS Diluted | 2.53% | 10.19% | |||
| Normalized Diluted EPS | -1.52% | -2.89% | |||
| Average Basic Shares Outstanding | 2.27% | 0.66% | |||
| Average Diluted Shares Outstanding | 2.27% | 0.66% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||